Eyenovia Inc. touted data from its phase II study evaluating the safety and efficacy of its high-precision ophthalmic microtherapeutics compared to conventional eyedropper treatment. The trial comes on the heels of a previous phase II study published in Therapeutic Delivery in October.
New York-based Eyenovia’s trial demonstrated that its microdosing achieved superior pharmacologic effects and bioavailability compared to dropper therapy, while reducing ocular side effects to 8% versus 66% for conventional topical treatment.
Get the full story at our sister site, Drug Delivery Business News.
The post Eyenovia touts phase II study data appeared first on MassDevice.
from MassDevice http://ift.tt/2hENLcK
Cap comentari:
Publica un comentari a l'entrada